U.S. Stem Cell, Inc. Announces Successful In-Human Results in Repairing Meniscus Tear After Autologous Stem Cell Therapy from Adipose or Fat Tissue
July 10, 2018 at 06:00 pm IST
Share
U.S. Stem Cell, Inc. announced it has demonstrated successful, in-human results in repairing meniscus tear after autologous stem cell therapy from adipose or fat tissue. Meniscal injuries are the most common knee injury in the United States with an annual average of incidence of 66 per 100,000, according to a 2014 article in the Journal of Orthopedics. Approximately 850,000 patients each year are surgically treated - often arthroscopically - for meniscal injuries. The paper outlines the case study of a 56-year-old male with a chronic meniscus injury. During the 12-month follow-up period, the patient reported a reduction in pain and an improvement in knee function. The arthroscopic images showing resolution were also consistent with quality of life improvements for the patient, including a reduction in pain and resumption of normal activities. The patient experienced very little downtime and was able to resume normal activities in less than 1 week.
U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.